Clinical Trial Update: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of entinostat and pembrolizumab for relapsed and refractory lymphoma, with status listed as active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Entinostat (entinostat)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, Relapsed | Phase 2 | Status: ACTIVE_NOT_RECRUITING